PF-05186462

• CAT Number: I034474
• CAS Number: 1235406-03-7
• Molecular Formula: C19H10ClF4N5O3S2
• Molecular Weight: 531.89
• Purity: ≥95%
• Synonyms: 5-chloro-2-fluoro-4-[2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide
• InChI: InChI=1S/C19H10ClF4N5O3S2/c20-13-6-17(34(30,31)29-18-28-27-9-33-18)14(21)7-16(13)32-15-2-1-11(19(22,23)24)5-12(15)10-3-4-25-26-8-10/h1-9H,(H,28,29)
• InChIKey: ZAGGUCLXSCVDCK-UHFFFAOYSA-N
• SMILES: C1=CC(=C(C=C1C(F)(F)F)C2=CN=NC=C2)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=NN=CS4)F

PF-05186462 (Cat No.: I034474) is a small-molecule glucagon receptor antagonist developed by Pfizer for the treatment of type 2 diabetes mellitus. By blocking glucagon receptor signaling in the liver, it reduces hepatic glucose production, thereby lowering blood glucose levels. Clinical studies have shown that PF-05186462 improves glycemic control and insulin sensitivity without significantly increasing hypoglycemia risk. Its mechanism highlights the therapeutic potential of targeting glucagon pathways in diabetes management, offering an alternative strategy to traditional insulin- and incretin-based therapies.

Reference

[1]. Jones HM, et, al. Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels. Clin Pharmacokinet. 2016 Jul;55(7):875-887.
[Content Brief]